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Biobanking functions within the Data Protection Regulation and EU legislation. Evaluation 
of data portability and informational self-determination and its impacts on the future of 
biobanking will be covered in the scope of the thesis. With all the discrepancies on consent 
and its evolution on sensitive data, there will be an evaluation of types of consent out there 
and their applicability and efficiency in the real sphere of biobanking. The target audience 
for the thesis are researchers, medical research professionals, and individuals in need of 
guidance for biobanking. The research is theoretical observed through EU legislation, 
national legislation and case studies. Recommendations from the study include strict 
supervision implementation when partnering with for profit companies or third parties on 
research projects, particularly being careful when a partnership between private and public 
sectors is initiated. The best suggestion in solving this problem is harmonization of the 
rights on storing and handling sensitive data. There should be a uniform rule on how 
private companies shall behave with such data. Adequate consent rights should be 
implemented with sensitive data. Lastly, there should be limitations or restrictions on 
compiling and using sensitive biological data.  
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Biobanks have become a popular means to do research and collect data on subjects through 
genomic research.  They have become viewed as research organizations- collecting data 
and samples from research subjects and making this material available, on application, to 
researchers. The aim of biobanks is to collect as much data as possible with as few 
limitations as possible. Many biobanks often do not even specify the type of research the 
materials will be used for.  
 
This can be problematic as it is only logical that in order to conduct medical research 
consent must be attained before conducting research on sensitive data.  
 
As biobanks process ‘personal data’, European data protection law applies in their day-to-
day operations. Despite the clear evidence that data protection law applies, there remains 
uncertainty about the exact application of the General Data Protection Regulation, 
hereinafter, GDPR. There are questions if open consent is legitimate is one such 
uncertainty. On top of this there is a wide range of opinions on what types of consent are 
applicable in the use of sensitive data. In addition to this, the GDPR requires that any 
consent be ‘specific’ and ‘informed’. This could pose a problem for biobanks operating 
with open consent as they cannot meet these requirements.  
 
Processing of personal data in biobank-based research involves sensitive data, such as 
health and genetic information, socio-demographic data, lifestyle and behavioral data, the 
Regulation provides requirements on regulation of such data. Additionally, principles for 
fair processing are addressed in the Regulation stipulating that data protection supervisory 
authorities should provide oversight and supervisory roles. 1 
 
With all this in mind, there is a clear lack of harmonization in the EU with regard to data 
protection in the biobanking industry. There are issues concerning cross-border exchange of 
 
1 Expert Group on Dealing with Ethical and Regulatory Challenges of International 
Biobank Research. 2013. Biobanks for Europe: A Challenge for Governance. Directorate-




personal data and sample transfers.2 In addition to this, there are issues with data security 
and confidentiality concerns with the exchange of sensitive patient data. 3 The GDPR is 
extremely relevant to biobanking and needs to be evaluated in understanding how to protect 
sensitive information from being breached by third parties. 
 
This thesis will examine how biobanking functions within the General Data Protection 
Regulation and EU legislation. There will be an evaluation of data portability and 
informational self-determination and its impacts on the future of biobanking. With all the 
discrepancies on consent and its evolution on sensitive data, there will be an evaluation of 
types of consent out there and their applicability and efficiency in the real sphere of 
biobanking.  With this there will be an evaluation of case law and how, if at all, patients can 
manage to keep their privacy and personal data from the hands of third parties through the 
process of biobanking.   
II Informational Self Determination 
2.1 Right to data portability and informational self determination 
The right to data portability has been a hot topic with regard to privacy recently as it has 
been included in legislation. Data portability allows an individual to get their data for their 
personal use from different services or databases storing their data. This allows them to 
move, copy, or transfer data in a safe secure way without compromising usability.  
 
The right to data portability gives an individual the right to receive personal data through 
machine-readable format for personal use or move it to another provider if they wish to do 
so by requesting a data controller to move the data directly to another controller of choice. 
According to the Open Data Handbook, machine-readable data is considered to be any data 
in a data format that can be automatically read and processed by a computer. This is lawful 
only when consent is given or for the purpose of performing a contractual obligation.  
 
2 Goebel JW, Pickardt T, Bedau M, Fuchs M et.al. Legal and ethical consequences of 
international biobanking from a national perspective: the German BMB-EU Coop project. 
European Journal of Human Genetics, 2010, Vol. 18, No. 5, pp. 522-525 
3 Schwarz E, Leweke FM, Bahn S, Liò P. Clinical bioinformatics for complex disorders: a 
schizophrenia case study. BMC Bioinformatics. 2009, Vol. 10 Suppl 12, pp. S6. 
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The right to data portability is outlined in article 20 of the General Data Protection 
Regulation (GDPR). Article 20(2) states “In exercising his or her right to data portability 
pursuant to paragraph 1, the data subject shall have the right to have the personal data 
transmitted directly from one controller to another, where technically feasible.” Patients 
contributing their samples for research have gained more rights against the controllers and 
processors of their data from the new GDPR. These rights include the right to consent, to 
information, to access, to rectification, to erasure, to restrict processing, to data portability 
and to object. However, some of these rights may be subject to limitations for scientific 
research purposes in certain instances. 
 
For our purposes it is important to note that the right to data portability only applied to 
personal data. Therefore, this leads to the idea that data portability does not apply to 
anonymous data.4 Yet, pseudonymous data that can clearly be linked to a specific 
individual is still within the scope of this right. Notably, the GDPR does not specify how 
individuals should make data portability requests. Therefore, requests could be made 
verbally or in writing. A request does not need to include the phrase ‘request for data 
portability’ nor does it need any reference to Article 20 of the GDPR.  
 
While the GDPR provides the option of data portability there are exemptions for biobanks 
from a number of GDPR principles and data subject rights if and when the personal data is 
being processed for scientific research. For instance, the data storage limitation principle 
can be revised and personal data can be stored for longer periods so long as they will be 
administered only for scientific research according to the provisions of article 89(1) of the 
GDPR and subject to implement technical and organizational measures required by the 
GDPR. 5 In addition to this, the GDPR allows for further data processing of personal data 
initially processed for a different for scientific research reasons, if there is a valid legal 
reason for the initial processing in the EU or Member State, hereinafter MS, laws exist 
allowing this extended processing.  
 
 






Informational self-determination is a fundamental element of human dignity but so are the 
rights to physical wellbeing, and we need the best in research and education if we want to 
guarantee European values granted to us. The data protection regulation is not very flexible 
since it was originally conceived before the rampant Internet era. The problem that arises 
through the process is the protection of personal data and how this can be achieved 
efficiently. Informational self-determination and how to maintain it also comes into 
question here.  
 
Informational self determination has German origins when in a well-known German census 
decision, the German Federal Court stated that informational self determination is a 
personality right, which ensures the individual the right to control how their personal data is 
issued and utilized. 6 Informational self determination has evolved but still remains closely 
linked to Westin’s definition of privacy as, “the claim of individuals, groups, or institutions 
to determine for themselves when, how, and to what extend information about them is 
communicated to others.”7   
 
Informational self determination is the ability of an individual to determine the disclosure 
and the use of their personal data, to control and to determine what others can find out 
them. In order for an individual to keep control over their data they must be informed about 
the purpose of processing and the identity of controllers, as well as all the rights that they 
have to their personal data.8 Put simply, the right to informational self-determination infers 
that it cannot function properly without transparency when processing the data.   
 
The concept of transparency can be found in Article 13 of the General Data Protection 
Regulation. Fair and transparent processing requires that the data subject be informed on 
the processing of their data, its purpose, how long the data will be stored, the right of 
access, rectification or erasure and on the right to lodge a complaint. 9 Additionally, Article 
 
6 German Federal Constitutional Court (BVerfG, 15 December1983). Online: 
http://www.servat.unibe.ch/dfr/bv065001.html#Rn003 
7 Westin, A. 1967, ‘Privacy and Freedom’, Bodley Head, London. p. 7  
8 Eva Fialova, Data Portability and informational self-determinaton, Masaryk University 
Journal of Law and Technology, Vol. 8:1, 2014 
9 Proposal for a Regulation of the European Parliament and of the Council on the protection 
of individuals with regard to the processing of personal data and on the free movement of 
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12 of the General Data Protection Regulation stresses that the controller should have 
concise, transparent, clear and easily accessible policies with regard to processing of 
personal data and the exercise of data subjects' rights.  
 
Informational self determination can be viewed as a proprietary right to personal data. Data 
portability is the transfer of an object, taken from one place to another and handed over, in 
our case the data transfer is the data subjects personal data. Data portability as proposed in 
the General Data Protection Regulation as two relatively separate rights, the right to obtain 
a copy from the controller and the right to data transfer.10 Even though, these rights 
enhance informational self-determination, they do not guarantee full control over personal 
data, as there is even differentiation on when the data portability can be extended based on 
the necessity of the material gathered from the data subject.   
 
Data portability increases informational self-determination of the data subject. Data 
portability should provide the data subject with control over the personal data.  
It is no question that informational self-determination is directly linked with information 
privacy. The data subject may determine to whom they disclose their personal data if at all. 
Their decision on this matter should be made freely without any undue influence from a 
third party for informational self-determination to be preserved. Nonetheless, the right to 
data portability, provides a means for providers to attract users with even more personalized 
services. These developments can result in lax rules on privacy protection of informational 
privacy of the data subjects for various reasons, whether to make profit or to promote 
research.  
 
2.2 Informational self determination and its effect on medical research  
Current developments in the genetic analysis and biobanks present new challenges to the 
right to informational self determination. Biobanks collect and use samples linking them to 
data, through this process researchers can gain access to personal characteristics of donors 
that may previously have been inaccessible to the donors themselves. The data subjects 
 
such data (General Data Protection Regulation), COM(2012) 11 final from 25 January 
2012.  
10 Eva Fialova, Data Portability and informational self-determinaton, Masaryk University 
Journal of Law and Technology, Vol. 8:1, 2014 
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concerned must give their informed consent. However, as we have seen, biobanks store 
samples and personal data for future research projects that are not yet specified at the time 
consent is given.11 Therefore, donors don’t actually know precisely what their samples and 
data will be used for. For this reason, general consent is often used. With this type of 
consent, donors consent to their samples and data being used for research in general, thus 
no specific research projects are specified. This means that data subjects do not have to be 
informed when a new project uses their samples.  
 
Informational self determination is key in medical research and the participants can 
implement their self determination right with regard to the research taking place. 
Informational self determination of patients applies to the purpose for which their personal 
data will be used. This is done through informed consent by a patient when they allow their 
biomedical data or treatments be used for a specific research or a general research.12 
However, in some cases like routine data used in scientific analysis, consent of the person 
cannot be obtained. When this occurs, the freedom of research for public interest must be 
weighed against the right to informational self determination. If the scientific analysis will 
create a positive outcome to benefit public interest it could outweigh the need for 
extraordinary steps to get consent. It is important to note that doctors and scientific 
researchers in this case do need to consult with an ethics committee before initiating a 
research project with sensitive biomaterials related to an individual. 13 
 
Biobanks research are susceptible to the same standards as research on human beings. 
Research in biobanks should respect the right to informational self determination. While 
there is a debate between ethics committees and data protection officers on how broad the 
information on what research field exactly their biospecimen will go to, the right to self 
determination still remains. Whether there is a broad scope such as medical research or a 
specific scope like cancer research the broadness doesn’t matter because self determination 
doesn’t specify that the donor be informed to make a decision. It is necessary for the donor 
 
11 Biobanks for Research, Opinion No. 24/2015, Swiss National Advisory Commission on 
Biomedical Ethics, online: https://www.nek-
cne.admin.ch/inhalte/E_Broschure_NEK_Biobank.pdf 
12 Peter LangKafel et al, Big Data in Medical Science and Healthcare Management, Ch.7 
p.91-95, 2014, De Gruyter 
13 Ibidem 
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to understand that consent can sometimes become uncertain. The donor needs to understand 
that biobanking is a new field and the future research methods can be uncertain, which may 
allow for changes in what the specimen are used. Exercising self determination will give 
answers but it may also be a leap into the uncertainty of a changing field. However, even if 
multiple parties handle the sensitive data in biobanks, biobank secrecy protects the rights of 
personality and the right of informational self-determination of the donors against private 
abuse and against government encroachments. 14 
III. The Consent Dilemma 
3.1 Informed Consent  
Informed consent is routine in healthcare especially when research is being done on 
humans. Institutions often recommend obtaining informed consent before performing any 
sort of research related to humans.  Over the years as bioethics has been on the rise, 
autonomy has become essential in modern medicine. 15 Due to this informed consent 
becomes a means of assuring patient autonomy in research. 16 
 
Informed consent is the process between a patient and a doctor where the doctor will give 
their patient information about certain treatments or possible research taking place and the 
patient must decide whether or not they wish to go take the treatment or test. The procedure 
of understanding the risks and benefits of the treatment or test is in fact informed consent.  
Informed consent is also based on the moral and legal premise of patient autonomy: the 
patient has the right to make decisions about their own health and medical conditions. 
Informed consent must be voluntary.  
 
There are three basic components to informed consent. They are disclosure, comprehension 
and voluntary agreement. Disclosure must be given to the relevant information to the 
 
14 Human Biobanks for Research, German Ethics Council, 2010 Deutscher Ethikrat, Berlin, 
ISBN 978-3-941957-12-1 
15 Wolpe, P.R, The triumph of autonomy in American medical ethics. In R. DeVries and H. 
Subedi (Eds.), Bioethics and society: Sociological investigations of the enterprise of 
bioethics, pp. 38–59. New York: Prentice Hall, 1998 
16 Faden, R.R. and Beauchamp, T.L., A history and theory of informed consent. New York 
& Oxford: Oxford University Press, 1986 
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subject on what the research is about. The patient must have comprehension of the 
information- meaning that they understand the information given to them. Lastly, the 
patient must give their voluntary agreement free from coercion and undue influence to 
participate in the research offered. 17 
 
A study by the Austrian Ethics committee has attempted to demonstrate the reasons why 
patients may donate their tissues or matter to research. The main reasons were contributing 
to a functioning system, enhancing medical science and research, and understanding how 
the system works.  
 
A common logic from a patient in the study was ‘because we all benefit from it.”18 This, 
however, only works in institutions where there is a publicly funded health care system, as 
their donation as a non-monetary exchange to benefit society as a whole. This would not 
seem like plausible logic in countries such as the US where expenses are paid out of pocket. 
In privately funded treatment usually there is no thought of benefitting others since it costs 
too much. Individuals are usually more motivated to find treatment for themselves only and 
do not wish their data to be shared with others since they did not pay for such testing or 
treatments, so they are not as apt to look out for society.   
 
Another response came to be “whatever is needed for good research.” 19Patients believed 
that they should donate to benefit the medical sciences. They believed that science and 
research is a gradual process and needs to be updated constantly, and if their donation can 
help then it is only better in the long run. This logic demonstrates that patients are in it for 
finding further cures for diseases.  
 
The last thinking is “because consent is needed for everything.” They have used the consent 
procedure because that is simply how the system works. Informed consent is used to protect 
 
17Required Components of Informed Consent, Institutional Review Board for Human 
Participants, Cornell University,  
https://www.irb.cornell.edu/forms/consent.htm, accessed 22.08.2018 
18 Ulrike Felt, Milena D. Bister, Michael Strassning, and Ursula Wagner, Refusing the 
information paradigm: informed consent, medical research and patient participation, An 
Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, Vol 13(1): p. 
96, 2009 
19 Ibid, p. 97 
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the relationship between the patient and the medical provider or research operator. This 
ideal was also demonstrated in the Convention on human rights and biomedicine where it is 
stated that ‘any part of a human body’ may only be used ‘if this is done in conformity with 
appropriate information and consent procedures.’20 Additionally, this was revised in the 
Declaration of Helsinki where it is explicitly stated that any research on human substances 
needs to be regulated through informed consent. 21 
 
3.2 Open Consent and the Data Protection Regulation   
 
Open consent is often the go-to solution in biobanks. It is also known as ‘broad consent’, 
‘general consent’, and occasionally ‘blanket consent.’ When using the open consent 
procedure, a biobank requests consent from the subject for all future research uses of their 
genetic material and data.22 It has three identifiers that make it unique from all the other 
forms of consent. In open consent (1) the research subject is actively giving consent only 
once to the biobank, (2) the subject is not asked to give consent to a specific research 
project or to an area of research and the subject gives consent for all future research, the 
research projects are not clearly defined, (3) researchers who want to conduct research on 
samples will apply to biobanks to use stored tissues and the biobank decides if they release 
the material or not the subject themselves have no say in this. 23 
 
Biobanks are constantly processing personal data, which means that they have a duty to 
comply with data protection law, which is currently under reform. The changes are relevant 
for biobanks as the new data protection regulation puts strict criteria on consent conditions. 
More specifically in open consent the subject only needs to confirm the consent to the 
biobank once. The consent given is then applicable for the extracted sample, the storage of 
 
20 Convention on human rights and biomedicine , Council of Europe, 1997: VII, Art. 22  
21 WMA Declaration of Helsinki– Ethical Principles For Medical Research Involving 
Human Subjects, Articles 25-32 
22 Dara Hallinen & Michael Friedwald, Consent, biobanking and data protection law: can 
open consent be ‘informed’ under the forthcoming data protection regulation?, Life 
Sciences, Society and Policy (2015) 11:1  
23 Ibid, p. 5 
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the sample and data, and any further research on the collected material. The GDPR 
explicitly states that any consent should be specific and informed. 24 
 
3.3 Broad Consent v.  Dynamic Consent  
The usual norm was to obtain broad consent from individuals participating in biobanks. 25 
Biobanks have a hard time to gain fully informed consent as future research in testing of 
tissues and sensitive matter is often unknown or variable. 26 Currently however there is an 
alternative form of consent available called dynamic consent. Dynamic consent focuses on 
the participant and involves ongoing communication between the biobank, donor, and 
researchers. 27 
 
Broad consents are not open thus giving broad consent means giving consent to future 
research of certain types.28 For this framework to work, each specific research project and 
independent ethics committee should evaluate projects and the biobank should update their 
donors with their options on how to withdraw their material. It is important to note that if 
anything in the framework changes the participants of the study must re-consent. 29 In the 
broad consent model, people are asked to re-consent only when there is an ethically 
relevant difference between two projects.30 If such a situation occurs, participants are then 
asked to re-consent, because a research ethics committee or the biobank believes there is 
something more to ask them about.  
 
 
24 Article 4(11) GDPR 
25 Steinsbekk KS, Myskja BK, Solberg B, Broad consent versus dynamic consent in 
biobank research: is passive participation an ethical problem? Eur J Human Genet 21:897–
902, 2013 
26 See further: Kaye J, Whitley EA, Kanellopoulou N, et al., Dynamic consent: a solution to 
a perennial problem? BMJ, 2011 
27 Dorit T. Stein and Sharon F. Terry, Reforming Biobank Consent Policy: A Necessary 
Move Away From Broad Consent Toward Dynamic Consent, Genetic Testing and 
Molecular Biomarkers, 17:12, 2013 
28 Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G: Should donors be 
allowed  to give broad consent to future biobank research? Lancet Oncol 2006; 7: 266–
269.  
29 Steinsbekk KS, Solberg B: Biobanks– when is re-consent necessary? Public Health 
Ethics 2011; 4: 236–250.   
30 Ibid 
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Dynamic consent is a ‘personalized, digital communication interface,’ which allows 
biobanks/researchers to establish continuous communication with research subjects.31 In 
this model, subjects are presented with specific project options and can constantly update 
their consent preferences in accordance with what studies they want to participate in and 
what they want do with their samples.  
 
With a dynamic consent model, participants will be asked for consent constantly because 
each project is considered a new project. 32Therefore, the participants will be asked to re-
consent both for essential and non-essential reasons. With broad consent participants are 
seldomly asked to re-consent, but when they are asked it is for an important reason or 
change in the research or testing.  
 
I think that the most appropriate form of consent in biobanking is dynamic consent. 
Dynamic consent allows for constant communication with the tissue donors and for them to 
change their preferences allowing them to be in control of where their materials go and to 
what study. The fact that the dynamic consent model informs research participants about 
the research they are involved in is essential in all types of research consent processes.  
This method better distributes detailed information compared with broad consent. 
Additionally, dynamic consent increases trust and willingness to participate in research. 
The aim of dynamic consent is to be more inclusive compared with regimens utilizing 
broad consent.  
 
This method of consent is also more applicable with the GDPR as it provides a specific and 
informed explanation of where the sample will be used and for what purposes. On the other 
hand, dynamic consent seems to go against Article 9(2) with regards to sensitive data, but 
this is a good thing as it can be an infringement of fundamental rights.  
 
31 Kaye, Jane, Edgar A Whitley, David Lund, Michael Morrison, Harriet Teare and Karen 
Melham. 2014. Dynamic consent: a patient interface for twenty-first century research 
networks. European Journal of Human Genetics 1–6., p.1 
32 Kristin Solum Steinsbekk, Bjørn Ka ̊re Myskja, Berge Solberg, Broad consent versus 
dynamic consent in biobank research: Is passive participation an ethical problem?, 
European Journal of Human Genetics (2013) 21, p. 898, 2013 
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3.4 Anonymization and Consent in Biobank Research  
The term ‘anonymized’ means that biological material is stored in conjunction with related 
information, such as medical treatment, donor’s age and so on, but all information that 
would allow identification of the research participant or patient is kept secret, either 
irreversibly (unlinked anonymized) or reversibly (linked anonymized). If the sample is 
linked anonymized, identification is possible by a code, to which researchers or other users 
of the material do not have access. In European documents, the term anonymized could 
mean either unlinked or linked anonymized. In the EU, ‘coded’ always indicates that 
researchers or other users have access to the code.  
 
According to many regulations and guidelines, there is no need to destroy a sample when a 
participant withdraws from a study, since anonymization can solve the problem. The 
European Society of Human Genetics writes that the use of ‘unlinked anonymized samples’ 
secures ‘absolute confidentiality’ and these samples can be used for new purposes without 
obtaining consent.33 The International Bioethics Committee (UNESCO) clarifies that 
consent may be withdrawn by the donor ‘unless such data are irretrievably unlinked to an 
identifiable person’ and that the data and biological samples should be treated as the donor 
wishes unless they are permanently unlinked.34The German Nationaler Ethikrat states that 
when samples are anonymized, then ‘donor interests calling for protection are not at issue’ 
and withdrawal of consent can be combated with anonymization.35 
 
The argument for anonymization is linked to the fact that information derived from a 
participant’s tissue cannot be used at their disadvantage if no one can find out their identity. 
The data subject does have the right to end participation in a study, but since it can be of 
importance to keep the sample for research, de-identification is the more preferred solution. 
Anonymization means that the participant is no longer participating; only the anonymous 
tissues are being observed, with no researchers gaining access to the identity of the donor.  
 
 
33 Godard B, Schmidtke J, Cassiman JJ, Ayme S: Data storage and DNA banking for 
biomedical research: informed consent, confidentiality, quality issues, ownership, return of 
benefits. A professional perspective. Eur J Hum Genet 2003; 11 (Suppl 2): S88–S122. 
34 UNESCO: International declaration on human genetic data. Eur J Health Law 2004; 11: 
93–107 
35 Nationaler Ethikrat: Biobanks for research, opinion. Berlin: Nationaler Ethikrat, 2004. 
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However, anonymization has some flaws in protecting participants' interests: 
1. It may not decisively cut the link to a specific individual, 
2. It prevents the use of samples for purposes such as diagnostics, 
3. It may not prevent harms to groups, and 
4. It does not rule out wrongdoing.36 
 
The ties from the individual cannot easily be cut.  Genetic information can be stored in 
medical journals, if an anonymous sample is run against a search of these journals, it can 
reveal whose sample it is. The publication of databases on the Internet, free for researchers 
to use, presents dangers to anonymity. If access of an identified sample is gained, more 
samples from the same person can be found by searching databases consisting of 
anonymous samples and comparing them. 
 
Anonymization prevents samples to be used for medical services. This is due to the fact that 
if a sample is de-identified it can no longer be used for diagnostics. Many individuals want 
to contribute to the medical world by offering their samples for the use of medical services, 
do not understand that protecting this sensitive information through anonymization does not 
leave them that option.  
 
On top of anonymization not protecting the interests of participants, anonymization of 
biobank samples may have a negative impact on research. For many studies, it is essential 
that researchers or those in charge of the biobank, have access to the identity of the samples 
so they can be linked to medical journals and register data. For quality reasons, researchers 
may also need to return to the original repository. A model in which continued use of 
identified samples is impossible if withdrawal is requested seems unsatisfactory, but 
anonymization also does not have all the answers quite yet.  
 
Anonymization should not be the default setting for researchers and biobank holders when 
requests of withdrawal occur. On the other hand, a request for withdrawal should not stop 
research on identifiable samples. Instead of the present emphasis on individuals’ right to 
 
36 Stefan Eriksson & Gert Helgesson, Potential harms, anonymization, and the right to 
withdraw consent to biobank research, European Journal of Human Genetics volume 
13, pages1071–1076 (2005) 
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withdraw consent to research on their biological samples for any reason, the clause on 
withdrawal in the Nuremberg Code be included in guidelines on biobank research.37 This 
would allow anonymization as a solution to the withdrawal of samples and promote further 
research on the tissue in question. Although there would also have to be reforms on 
researchers requests of the samples and a way to ensure that the information of the donor 
doesn’t get released through medical journals.  
 
3.5 Privacy Self-Management  
The new General Data Protection Regulation states that personal data may only be 
processed based on one of the following six grounds: it is required by a legal obligation, it 
is carried out to protect a vital interest of the individual, it is carried out for the public 
interest, it falls within a legitimate interest of the data controller, it is necessary for the 
performance of a contract, or it is based on the consent of the individual.38  Consent for our 
purposes is an essential addition to the GDPR, particularly informed consent, which allows 
the individual to agree to data processing options and who gets access to their data. Privacy 
self-management allows people the right to take notice of how their personal data is being 
collected and used and need to decide whether or not they consent to such use of their data. 
 
Daniel J. Solove coined the term ‘privacy self-management’ as a bundle of rights providing 
people with control over their personal data, through which individuals can decide for 
themselves the costs and benefits of collecting, using, or disclosing their information. 39 
Privacy self-management takes a neutral stance on whether certain forms of collecting data 
or good or bad, and actually focuses on individuals consent to various privacy practices.  
 
Privacy self-management originates from the Fair Information Practices, also commonly 
referred to as the Fair Information Practice Principles (FIPPs). 40 The FIPP was discussed in 
 
37 Ibid 
38 Tuukka Lehtiniemi and Yki Kortesniemi, Can the obstacles to privacy self-management 
be overcome? Exploring the consent intermediary approach, Big Data & Society July-
December 2017: 1-11 
39 Daniel J. Solove, Introduction: Privacy Self-Management and the Consent Dilemma, 
Harvard Law Review, Vol. 126:1880, 2013 
40 Robert Gellman, Fair Information Practices: A Basic History, Bob Gellman 9–10, 2012, 
Online: https://bobgellman.com/rg-docs/rg-FIPshistory.pdf 
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a report to discuss concerns about data being increasingly digitized. FIPP principles 
included (1) record systems of personal data must be transparent, (2) individuals should be 
able to find out about such record systems, (3) the right to prevent personal data from being 
used for new purposes without consent, (4) the right to correct or amend one’s records, and 
(5) responsibilities on the holders of data to prevent its misuse.41 These principles helped 
shape the OECD Privacy Guidelines of 1980 and the APEC Privacy Framework of 2004.42 
 
While privacy self-management can provide benefits there are a few problems that arise.  
1. Individuals usually do not read privacy policies 
2. If the policies are read, they are not always understood 
3. If the privacy policies are read and understood, then individuals do not have enough 
information to make an educated and informed decision  
4. If the terms are understood decision-making can always be skewed making it hard 
to make an informed decision.  
 
 
Although privacy self-management seems like it can be good for the individual, the 
individual still cannot appropriately self-manage their data. The problem of scale comes 
into play. The problem of scale is related to the number of companies collecting and using 
data, making it impossible for an individual to be able to manage privacy with everyone 
individually. Another example is the problem of aggregation. The problem of aggregation 
 
41 U.S. Department of Health, Education & Welfare, Report of the Secretary's Advisory 
Committee on Automated Personal Data Systems: Record Computers and the Rights of 
Citizens, 41-42, 1973, Online: https://www.justice.gov/opcl/docs/rec-com-rights.pdf 
42 Daniel J. Solove, Introduction: Privacy Self-Management and the Consent Dilemma, 
Harvard Law Review, Vol. 126:1880, 2013 
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is the fact that privacy harms often consist of an aggregation of different pieces of data. 
Thus, an individual has no way to assess whether any information disclosed about them, 
when combined with other data, can reveal something that can cause them harm later down 
the road.  
 
Privacy law often relies too much on privacy self-management. Privacy self-management 
cannot achieve privacy alone. Many privacy issues are inherently linked with the consent 
dilemma. A coherent approach to consent must be developed in legal framework, taking 
into account how individuals actually make decisions about their personal data. It is also 
important to develop more substantial privacy rules and timing necessary for consent. 
While, an individual can take part in privacy self-management it is important to remember 
that individuals can often only participate in this selectively and if they fully understand 
what they are consenting to.  
 
3.5.1 Information Privacy and control of personal data  
Informational self determination is an updated form of the right of privacy, protecting 
citizens from the unlimited gathering, storage and use of private information. It is 
considered the right of private individuals to know who is collecting and using information 
about them at any given time and under any circumstances. The right of informational self 
determination prevents enterprises or government agencies from doing whatever they want 
with the data of private citizens. This legislation guarantees the fundamental right of 
individuals to determine whether and how their data should be used or released. 
 
The German Constitutional Court has developed the right to informational self-
determination in 1983, in its famous Census decision (Case No. 1 BvR 209/83, 15 Dec. 
1983, 65 BVERFGE 1.) The court declared the Census Act of the Federal Parliament 
unconstitutional based on the provisions of Article 1 (human dignity) and Article 2 (right to 
free development of personality) and ruled that “basic right warrants […] the capacity of 
the individual to determine in principle the disclosure and use of his/her personal data,” and 
further “the authority of the individual to decide himself, on the basis of the idea of self-
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determination, when and within what limits information about his private life should be 
communicated to others.” 43  
 
One of the biggest dilemmas in data protection of personal data has been finding a balance 
between informational self-determination and an individual’s control over their data with 
the competing interest of the one’s collecting, using and processing their data.  
 
A patients’ genetic data is considered sensitive data. This encompasses all personal data, 
which is particularly sensitive in relation to fundamental rights and freedoms, meriting 
specific protection as the context of their processing could create significant risks. It is 
forbidden to share such personal data especially a patient’s health and genetic data, the only 
exception to this is if it falls under Article 9, paragraph 2 of the General Data Protection 
Regulation.  
 
Under Article 9, paragraph 2 such information can be given up only for a few reasons, 
encompassed below.  
1. If the patient gives explicit and unambiguous consent to the use of their data 
2. If the patient makes the data manifest himself or herself 
3. If it is in the patient’s vital interest 
4. For healthcare purposes 
5. For public interest in the area of public health  
6. To carry out the right of the person that controls patients’ data in the field of 
employment, social security and social protection law 
7. Substantial public interest 
8. Processing is necessary for archiving purposes in the public interest, scientific or 
historical research purposes or statistical purposes44 
 
 
43 Rouvroy Antoinette, Poullet Yves. The right to information self- determination and the 
value of self-development: reassessing the importance of privacy for democracy, 2009, p.45 
44 The new EU Regulation on the protection of personal data what does it mean for patients, 
A guide for patients and patients’ organizations, European Patients Forum, Online: 
http://www.eu-patient.eu/globalassets/policy/data-protection/data-protection-guide-for-




Regulation 2016/679 provides a lot of insight for the protection of personal data. This new 
regulation aims to empower people of their rights and the right to be informed gives them 
more control over their personal data. These protections are highly relevant for patients in 
healthcare and provide answers for research purposes as well.  The details can be reviewed 
in the chart below.  
 
Right Provided  Article Number What’s in it for the 
patient? 
What to be careful of  
To access one’s own 
personal data 
 
Recital 63 Article 
15 
 
• The right to access 
your personal data is 
part of your 
fundamental right to 
data protection 
 • The right to access 
your medical record is 
explicitly mentioned in 
the new Regulation  
• If you request a copy 
of the personal data 
being processed by a 
data controller about 
you, they are obliged to 
provide it to you 
• The controller can charge a fee 
for the administrative cost of 
providing the data when you 
request it more than once. 
Article 12 also explains that a 
fee can be charged when the 
request for data is “unfounded” 
or repetitive. 
 • If you provided your data in 
the context of a scientific 
research, there may be 
exemptions to this right 
Right to data 
portability/to 
transfer your data 
from one data 





• When you have 
consented to provide 
your health data, and 
that it is in a machine 
readable format (e.g. in 
electronic form), you 
can request to receive a 
copy in order to 
transfer it to another 
entity or person, and 
you can also demand 
that it is transferred 











• There is no firm obligation for 




Right Provided  Article Number  What’s in it for the 
patient? 
What to be careful of 
Right to object to 
the processing of 
your data 
 
Article 21  Under the new 
regulation you can 
object to the processing 
of your data by a 
controller under these 
circumstances:  
• If the processing 
happens for a task 
performed in the public 
interest (Article 6 
paragraph 1(e)) 
 • If the processing 
happens for the 
legitimate purpose of 
the controller (Article 6 
paragraph 1(f)) 
 • If it happens in the 
context of direct 
marketing 
In research, you can object to the 
processing, unless it is necessary 
for a task carried out for reasons 
of public interest (Article 21 
paragraph 6) 
 
Right to rectification 
or erasure of data 
 
Article 16  You can ask for the 
rectification of 
inaccurate personal 
data (e.g. in your 





Right to be forgotten  Article 17  You can have your data 
erased. This is 
especially the case if:  
• you have withdrawn 
consent and the data 
controller has no other 
grounds for processing 
your data  
• if there is no longer a 
purpose for processing 
it, in accordance with 
the principle of limited 
storage and data 
minimization. 
 • if the processing is 





There are derogations to your 
right to have data erased in 




Table 1 EU Law regarding patient rights to data privacy45 
 
While discussing biobanking and data protection of adults it is vital to note that biobanking 
samples of children is increasing at an even higher rate. This has become the case because 
the percentage of disorders with genetic backgrounds is greater than those in adults. 46 The 
Netherlands has several large-scale pediatric biobanks such as the Amsterdam-Born 
Children and Their Development Study (ABCD)47 and the KOALA cohort study.48 
Pediatric biobanking faces traditional challenges of biobank privacy protection along with 
 
45 The new EU Regulation on the protection of personal data what does it mean for patients, 
A guide for patients and patients’ organizations, European Patients Forum, Online: 
http://www.eu-patient.eu/globalassets/policy/data-protection/data-protection-guide-for-
patients-organisations.pdf, accessed September 1st, 2018  
46 Verma IC, Puri RD (2015) Global burden of genetic disease and the role of genetic 
screening. Semin Fetal Neonatal Med 20(5):354–363  
47 ABCD Study, http://www.abcd-studie.nl/?page_id=238. Accessed 30 March 2020  
48 KOALA Study, https://www.koala-study.nl/node/12645. Accessed 30 March 2020  
Right Provided  Article Number What’s in it for the 
patient? 
What to be careful of  
Rights when there is 
a breach  
Article 34  If there is a security 
breach and your 
personal data is unduly 
disclosed, accessed, or 
destroyed, the data 
controller should keep 
you informed about the 
breach if it is a threat to 
your rights or 
freedoms, unless they 
have taken other 
measures to protect the 
data (like key coding 
the data). They should 
also inform their 
national supervisory 
authority of the breach. 
It is important to ensure that 
supervisory authorities are 
accurately informed of the threat 
to rights and freedoms 
represented by undue disclosure 
of health or genetic information. 
 




Article 13, 14  The data controllers 
have an obligation to 
provide some 
information to you. 
They have to provide it 
in a concise, 
transparent, intelligible 
and easily accessible 
form, using clear and 
plain language. 
There is an exemption, in the 
case of research, if it proves to 
be a “disproportionate burden” 
to provide this information to 
data subjects. When data 
subject’s requests for 
information are “unfounded” or 
repetitive, controllers can charge 
you to provide this information 
(Article 12) 
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additional challenges. Specific additional challenges are related to the young age of donors 
which hinders responsible decision-making capacity legally. The rights of these children 
need to be protected at all points. While initially the rights are initially exercised by their 
legal representatives the children gain access to exercise their rights, thus it is essential that 
the information is handled properly and with proper transparency.  One question I came 
upon and will focus on with child pediatric cases is what rights do a child’s legal 
representatives have to control whether the child’s samples will be stored in a biobank, and 
what rights does that child later have upon reaching the legal age of decision-making 
capacity? 49 
 
The Convention of the Convention on Human Rights and Biomedicine (CHRB) from the 
Council of Europe (1997)50 is a good place to start to examine these issues. According to 
article 5 and 6 of this convention together with the (non-binding) International Declaration 
on Human Genetic Data51, free and informed consent to storage of a child’s residual 
samples should be authorized by the child’s parents or representatives. Additionally, the 
Biomedicine Convention confirms people’s ‘right to know’ any data collected about their 
health as well as ‘their right not to know.’  ‘The right not to know’ simply means that they 
do not wish to be informed of information or they do not wish to access it. This right to not 
know is interesting to note in cases of children with mental disabilities because the children 
may never have the power to comprehend the information but their parents or guardians can 
use the genetic research to help others with similar cases to gain more information on 
particular genetic mutations. However, it is important to note that these rights are not 
 
49 Elcke J. Kranendonk, Raoul C. Hennekam, M. Corrette Ploem, Paediatric biobanking: 
Dutch experts reflecting on appropriate legal standards for practice, Eur J Pediatr (2017) 
176:75–82  
50 Council of Europe (1997) Convention for the Protection of Human Rights and Dignity of 
the Human Being with regard to the Application of Biology and Medicine: Convention on 
Human Rights and Biomedicine. Oviedo: Council of Europe. Online: https://rm. 
coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent? 
documentId=090000168007cf98  
51 United Nations Educational, Scientific and Cultural Organization (UNESCO) (2003) 





absolute and can be overruled in a case of vital interests or donors or their relatives 
according to paragraph 70 CHRB Explanatory report. 52  
 
The second international guideline that is relevant to children, while has little mention on 
their explicit right, is the Guidelines on Human Biobanks and Genetic Research Databases 
(HBGRD). Paragraph 45 of the CHRB Explanatory Report does note that the opinions of 
minors should carry increasing weight in decisions in keeping with their age and maturity. 
This issue of affirming children’s right to express their own opinions, is similarly tackled in 
article 12.1 of the United Nations Convention on the Rights of the Child (UNCRC): ‘States 
Parties shall assure to the child who is capable of forming his or her own views the right to 
express those views freely in all matters affecting the child, the views of the child being 
given due weight in accordance with the age and maturity of the child.’ These two 
conventions help to ensure that while the child does have a guardian that tackles their 
biobanking information while they are not capable, the child does have a right to have a say 
and weigh in on their personal choices when they are mature enough. However, it is 
interesting to note that in the conventions it is never concretely specified what is maturity 
and how to explicitly evaluate it in different cases.  
 
Notably, the Dutch legislative framework permits adolescents aged 16 and older in 
principle to decide independently about their treatment and, after acceptance of an 
amendment bill, about participating in biomedical research.53 While this is progressive to 
allow children to have control over their data at a young age it seems to make the matter 
more complex. It is complicated to inform a child at an adolescent age about their rights 
since the matter may be too complicated for their young mind to comprehend fully. On the 
other hand, it seems like a great step in transparency and easy accessibility to information 
they are entitled to and should be followed up on if the child is involved and comprehends 
the totality of their actions. The right to termination in special requests of the child donor 
 
52 Council of Europe (1996) Explanatory report to the Convention on Human Rights and 
Biomedicine. Strasbourg: Council of Europe. Online:  
https://rm.coe.int/CoERMPublicCommonSearchServices/ 
DisplayDCTMContent?documentId=09000016800ccde5.  
53 Elcke J. Kranendonk, Raoul C. Hennekam, M. Corrette Ploem, Paediatric biobanking: 




should be valued in accordance with the unique Dutch law provided.  However, children 
under 16 do not yet qualify for independent consent does not mean that they do not need to 
be informed about their participation and should not be involved in the decision-making 
process.  
 
All children have the right to be informed and should be able to take part in the process 
since later in life they will have the power to control their biospecimen in the future. It is 
inherent to keep them up to date so they can make a knowledgeable decision when the time 
comes for them to take charge if they are willing.  
IV Biobank Regulation and Data Protection  
Biobanks form a key infrastructure layer supporting genetic research. However, as 
biobanks have become more popular and the importance of samples and data in research 
has grown collecting samples with no particular purpose has been essential in the industry 
to analyze expanding data sets. 54 The current strict conditions on traditional consent 
methods in medical research are contradictory for biobanks, there is a requirement to 
specify the specific research in advance and to gain consent from the participants, which is 
directly going against the method of biobanks to extract maximum research necessary to 
yield results in collecting samples.   
 
There are arguments in place today that biobanks are a unique research concept and should 
be given some leeway. Such ideas are backed up by pro-autonomy and self determination 
concepts. There are two-sides to this coin, on the one side it can be argued that biobanking 
has a lot of potential on health research and that these strict requirements can hinder the 
huge research yields that biobanking can provide in the health sector.55 On the other side, it 
 
54 Expert Group on Dealing with Ethical and Regulatory Challenges of International 
Biobank Research, 2013 
55 Hansson, Mats, Joakim Dillner, Bartram Claus, Carlson Joyce, and Gert Helgesson, 
Should donors be allowed to give broad consent to future biobank research?, Lancet 
Oncology 7: 267, 2006, p. 267 
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can be argued that such physical risk that comes with invasive research is different to the 
informational risk that is ever present in biobank research. 56   
 
Simple storage of a sample in a biobank, however, doesn’t involve any direct physical 
harm. According to the German Nationaler Ethikrat, bodily risks are prohibited from the 
start because the samples being used for research are already separated from the body.57  
This means that there is a distinct difference between biobank research and research 
conducted directly on the human body.  In fact, the Declaration of Helsinki states that 
medical research involving human subjects ‘includes research on identifiable human 
material or identifiable data.’58  
 
Although there is no direct physical harm, this does not mean that there is no other types 
harm in biobank research. There is indirect physical harm. Samples collected in a clinical 
setting are important for future care of patients, with many parties interested in the results 
of the testing on sampling and potential solutions they may yield as a whole in the medical 
world. If researchers gain unrestricted access, samples can be over sampled/ overused, and 
this will lead to sparse samples for future care. This could in turn not just harm the research 
sphere but can lead to side effects for patient’s physical health over time since they may 
need more samples from the patient and will not provide results.  
 
Another common form of harm see in biobank research is nonphysical harm. Nonphysical 
harm means that sensitive information has ended up in the wrong hands and is being 
exploited to disadvantage an individual. The information is extracted from samples.  If the 
biobanks are implementing a high safety standard, then the nonphysical risk is relatively 
small. A frequent example of this is demonstrated with the insurance companies using 
genetic information to discriminate against people with certain genetic dispositions. 59 This 
 
56 See: Mascalzoni, Deborah, Andrew Hicks, Peter Pramstaller and Matthias Wjst, 
Informed Consent in the Genomics Era, PLOS Medicine 5: 9, 2008 
57 Nationaler Ethikrat: Biobanks for research, opinion. Berlin: Nationaler Ethikrat, 2004.  
58 Stefan Eriksson and Gert Helgesson, Potential harms, anonymization, and the right to 
withdraw consent to biobank research, European Journal of Human Genetics (2005) 13, 
p.1072 
59 Stefan Eriksson and Gert Helgesson, Potential harms, anonymization, and the right to 
withdraw consent to biobank research, European Journal of Human Genetics (2005) 13, 
p.1072 
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kind of discrimination can lead to economic and social harm to the individual. 60 That is 
why many individuals get concerned with keeping their privacy safe since facts that an 
individual may want to keep private are communicated to others without their consent, 
psychological or social harm may arise, particularly stigmatization and discrimination at 
work, as anxiety and disturbed relationships. 61All these three potential harms are why there 
is a debate and need for protection of privacy to be in force for patients, as well a way to 
withdraw information if necessary.  
 
The GDPR protects individuals with regard to the processing of personal data and on the 
free movement of such data. It has been transposed into national law. The objective of this 
Regulation is to secure the free flow of personal data within the internal market making 
sure to ensure a high level of protection for all citizens and their consent procedures 
through the process. Health data has special protection within Article 9(1) of the GDPR 
where the processing of sensitive data in general is prohibited. Still, the protection is not 
absolute and there are circumstances where the public interest overrides the privacy 
interests of the individual. This is due to the fact that health data is highly sensitive and 
therefore requires a high level of protection. Biobanks as an infrastructure for research were 
still unknown at the time the GDPR was drawn up, so it is not easy to find the right 
category for them. 62 Due to the lack of popularity of biobanking at the time biobanks are 
not explicitly mentioned in the regulation.  Biobanks are not research themselves, but they 
belong to the wider research domain. Thus, biobanks for health research can also be seen as 
public health tools as they share many legal features with monitoring and surveillance 
institutions. 63 
 
The principle of purpose, in combination with the principles of non-excessiveness and 
fairness, with regard to data collections like biobanks is described in Article 5 and 9(2) of 
 
60 Radetzki M, Radetzki M, Juth N: Genes and insurance. Cambridge: Cambridge 
University Press, 2003.  
61 Eriksson S: Should results from genetic research be returned to research subjects and 
their biological relatives? Trames J Humanities Soc Sci 2004; 8: 46–62.  
62 Tobias Schulte in den Baumen , Danielle Paci, Doloris Ibarreta, Data Protection and 
Sample Management in Biobanking – A legal dichotomy, Genomics, Society and Policy, 
Vol.6, No.1 (2010) ISSN: 1746-5354 
63 M. Verschuuren et al. The European data protection legislation and its consequences for 
public health monitoring: a plea for action. Eur J of Public Health 2008; 18(6): 550-551 
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the GDPR. Article 9(2) highlights the data protection problems that biobanks are currently 
facing. Large-scale population-based biobanks require substantial investments and are part 
of a long-term infrastructure for medical research. Accordingly, from the research 
perspective, the purpose is exactly to serve as a tool for long-term genome-based 
research.64 The Data Protection Regulation states that the purpose of the processing must be 
legitimate and explicit at the time of the data collection. 
4.1 Consent in Biobanking 
Biobanks are constantly processing personal data, which means that they have a duty to 
comply with data protection law, which is currently under reform. The changes are relevant 
for biobanks as the new data protection regulation puts strict criteria on consent conditions. 
 
Under the GDPR specific mechanisms must be set in order for consent to be valid:  
. Data subjects are provided with a clear explanation of the processing to which they 
are consenting; 
. The consent mechanism is genuinely of a voluntary and "opt-in" nature;  
. Data subjects are permitted to withdraw their consent easily; 
. The organization does not rely on silence or inactivity to collect consent.  
 
Additionally, the Regulation specifies the criteria on consent should be obtained:  
. If the data subject's consent is given in the context of a written declaration, which 
also concerns other matters, the request for consent shall be presented in a manner 
that is clearly distinguishable from the other matters.  
. Consent must be requested in an intelligible and easily accessible form, using clear 
and plain language. 
. Consent must be freely given.  
. Consent must be informed, as specified in the GDPR.  
. Consent must be provided by a clear and affirmative action. 
. Consent can be provided in writing, by electronic means, as well as orally. 
 
 




Article 4(11) of the GDPR defines consent as: “any freely given, specific, informed and 
unambiguous indication of the data subject's wishes by which he or she, by a statement or 
by a clear affirmative action, signifies agreement to the processing of personal data relating 
to him or her.”  In addition to the amended article 4(11) guidance on how to comply with 
the main elements of consent are laid out in Article 6, 7 and in recitals 32, 33, 42, and 43. 
Lastly, provisions and recitals are included on the withdrawal of consent confirms that 
consent should be a reversible decision and data subject has control over this.  
 
As biobanks process ‘personal data’, European data protection law applies in their day-to-
day operations. Despite the clear evidence that data protection law applies, there remains 
uncertainty about the exact application of the regulation. There are questions if open 
consent is legitimate is one such uncertainty. On top of this there is a wide range of 
opinions on what types of consent is applicable in the use of sensitive data. In addition to 
this, the GDPR requires that any consent be ‘specific’ and ‘informed’. This could pose a 
problem for biobanks operating with open consent as they cannot meet these requirements.  
 
Processing of personal data in biobank-based research involves sensitive data, such as 
health and genetic information, socio-demographic data, lifestyle and behavioral data 
provide requirements on regulation of such data. Additionally, principles for fair processing 
are addressed in the regulation stipulating that data protection supervisory authorities 
should provide oversight and supervisory roles. 65 
 
4.1.1 The right to withdraw to Biobank research 
Thanks to the Declaration of Helsinki 1964 the demand for unrestricted individual rights to 
withdraw consent to participate in research is on the rise. According to the Helsinki 
Declaration, all research subjects have the right to withdraw consent to participate at any 
time without punishment, regardless whether the research was conducted on their bodies or 
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on their stored biological samples. 66  Although there was already the concept of individual 
rights in to stop participation in studies before in the Nuremberg Code of 1947, the Helsinki 
Declaration provided a clearer, easier way on how to do this.  
 
The Nuremberg Code saw research, as a common good and idealized experimental 
subjects, as a greater good for humanitarian projects leading to different view on 
withdrawal rights67, whereas the Helsinki Declaration provided the individual the right to 
withdraw regardless of the reasoning allowing for more freedom. The right to withdraw 
consent does not imply a right to withdraw results that have already accumulated, rather it 
implies that new data cannot be obtained, and that existing data must be maintained in an 
impersonalized form. 68 
 
The Council for International Organizations of Medical Sciences (CIOMS) states in its 
International ethical guidelines for biomedical research involving human subjects that 
informed consent ‘‘protects the individual’s freedom of choice and respects the individual’s 
autonomy’’ and that research participants should be informed when they ‘‘will be free to 
withdraw from research at any time without penalty or loss of benefits to which he or she 
would otherwise be entitled.”69 It should be noted that researchers should never conduct 
research without consent form the participants, however CIOMS allows exceptions. 
CIOMS only exception is when an ethical review committee gives its approval, this can be 
done if the research is considered important enough and involves no more than minimal 
risk, the rights and interests of the subjects are not violated, and privacy and confidentiality 
are assured. 70  Individual consent should only be mandatory is the researcher cannot prove 
that the consent is a big obstacle that will make the research unviable. 71 
 
66 World Medical Association. Declaration of Helsinki, Ethical Principles for Medical 
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69 CIOMS: 2002, International Ethical Guidelines for Biomedical Research Involving 
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70 Gert Helgesson and Linus Johnsson, The right to withdraw consent to research on 
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The right to withdraw consent is also protected in the Convention on human rights and 
biomedicine. Article 5 of the Convention on human rights and biomedicine, issued by the 
Council of Europe, states that all research subjects ‘‘may freely withdraw consent at any 
time.72’’ This is backed up in the convention with Article 2, which states that the ‘‘interests 
and welfare of the human being shall prevail over the sole interest of society or science.73’’ 
Although research specifically on biological materials is not explicitly stated the 
Explanatory Report that the convention encompasses ‘‘all medical and biological 
applications concerning human beings’’74, including research.  
 
Article 7(3) of the GDPR prescribes that the controller must ensure that the data subject can 
withdraw consent as easily as they can give consent and at any given moment. The GDPR 
does not say that giving and withdrawing consent must always be done through the same 
action. The requirement of an easy withdrawal is described as a necessary aspect of valid 
consent in the GDPR. If the withdrawal right does not meet the GDPR requirements, then 
the consent mechanism of the controller does not comply with the GDPR. In addition to 
this, controllers have an obligation to delete data that was processed on the basis of consent 
once that consent is withdrawn, assuming that there is no other purpose justifying the 
continued retention.75 
 
According to extensive research most ethical guidelines are for the protection of withdrawal 
of consent in biobank research. However, there are no explicit explanations as to why this 
should be an available remedy within these documents. Invoking the right to withdraw 
consent is important for the public to have trust in researchers and will promote more 




72  Council of Europe: 1997, Convention for the Protection of Human Rights and Dignity of 
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Human Rights and Biomedicine, Oviedo, article 5 
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4.2 Legal Application of Biobanking  
4.2.1 The US  
The case AMP v Myriad had a verdict drawn down from the Supreme Court that simply 
identifying a particular DNA gene sequence is not sufficient enough to grant the person 
who identified it a comprehensive and exclusive patent regarding said sequence. This case 
is interesting in observing patents of biological materials and is interesting to apply in the 
case of academic research patenting and its freedom, which will be discussed further in the 
chapter.  
 
Myriad Genetics, Inc. is a genomic research firm whose mission is to learn what various 
sequences of DNA in the human genome actually do. In the course of their research, and in 
collaboration with other scientists from other groups, Myriad’s scientists made an 
extraordinarily useful discovery of two genes now known as BRCA1 and BRCA2. The 
influence of these genes can elevate the risk of a woman developing cancer. 
 
As a result, after the discovery was made, the company began offering screening tests to 
members of the public able to afford them and filed for patents related to the discovery and 
associated assets. Certain patents were granted, and Myriad claimed exclusivity over 
various tests and other items related to the genes in question. 
 
Myriad’s claiming exclusivity was controversial and problematic for many reasons. If 
valid, the patents essentially would give Myriad “ownership” of the genes, for practical 
purposes and applications. This ownership could have been used to impede scientific 
progress and health care efforts including the prevention of: 
1. Academic researchers from pursuing studies in connection with the genes; 
2. Labs from offering tests related to the genes; and 
3. Medical professionals from offering treatments related to the genes. 
A coalition of petitioners from academic researchers, labs and medical professionals filed 
suit seeking to have Myriad’s patents invalidated so that research, tests and treatments 
related to the BRCA1 and 2 genes could be pursued unrestricted.  
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Myriad argued that once a gene is isolated, and distinguishable from other genes, it could 
be patented. By patenting the genes, Myriad gained exclusive control over diagnostic 
testing and further scientific research for the BRCA genes. Petitioners argued that patenting 
those genes violated §101 the Patent Act because they were products of nature. They also 
argued that the patents limit scientific progress. §101 limits patents to "any new and useful 
process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof." 
 
The questions the court had to deal with were:  
1. Can genetic research resulting in a major scientific breakthrough be considered 
patentable subject matter given its contribution to science and the humanities? 
2. Patentable research does not distinguish between natural occurring versus 
synthetically made genetic segments? 
 
The court decided that patentable subject matter does not rely upon "major scientific 
breakthrough" accomplishments or mannerism of its "contribution to science and 
humanities", its sole patentable evaluation should be based on statutory constructs of 
"Novelty, Utility, Non-Obviousness", balanced with statutory patent ineligible subject 
matter of "Natural Phenomenon, Law of Nature, Abstract Ideas."  The court adjudicated 
that natural occurring genetic segments are patent ineligible based on statutory bar of 
"Natural Phenomenon, Law of Nature” since the segments already existed without human 
intervention and were only identified by humans for latter scientific research. On the other 
hand, synthetically made genetic segments are considered patentable subject matter since 
they do not occur naturally in nature, thus created specifically by human intervention.  
 
In the end, the Supreme Court held that Isolated DNA was patent ineligible, but synthetic 
Composite DNA was patent eligible under 35 USC 101. 
 
This case paved the way in the scientific patenting world of the US, but it also shone a light 
on how collaborative research should be handled. The idea that no naturally human derived 
materials can be patented especially on a collaborative project shows a parallel as to some 
issues discussed later on university run biobanks. The court case here could help in future 
cases not just in the scientific community but also in researcher communities for further 
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biobank studies, it can also provide a good example on abolishing the concept of 
‘professor’s privilege.’  
 
4.2.2 The UK 
 
Human rights often come into play in biobank regulations and as an example of such 
recently there have been cases discussing informatization of the body.  
 
Informatization of the body is ‘a process where the human body is recast as an entity 
constituted by information.’76 Informatization of the body undermines the traditional 
distinction between the body itself and information about the body. Van der Ploeg argues 
that the body and data can no longer be separated and that informatized bodies have moral 
and legal obligation to be protected. 77  
 
In short, this means that the body is considered an entity made of information. This is 
referring to the fact that the medical industry is using the body as a source of gathering 
data, so in essence, separating the body and using the samples extracted as a source of 
information rather than seeing the physical body. For instance, this can be seen in all our 
information going in patient records in databases and registries so other medical 
professionals can access our data.  
 
There was a case in the EU that merged the idea of the Data Protection Convention and 
human rights. The Data Protection Convention should protect rights and freedoms of the 
research subjects’ matter. Particular focus should be given to article 8 of ECHR and the 
Data Protection Directive. 78Strasbourg case law has demonstrated that ECHR article 8 
 
76 Lee A. Bygrave, The Body as Data - Biobank Regulation via the Back Door of Data 
Protection Law, 2 Law Innovation & Tech. 1, 2010, p. 6 
77 See further: Irma van der Ploeg, Genetics, Biometrics and the Informatization of the 
Body', 2007, 43 Annali dell' Istituto Superioredi Sanith 47 
78 Lee A. Bygrave, The Body as Data - Biobank Regulation via the Back Door of Data 
Protection Law, 2 Law Innovation & Tech. 1, 2010, p. 11 
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requires the processing of personal data to be regulated in accordance with basic data 
protection principles. 79  
 
The Grand Chamber of the European Court of Human Rights (ECtHR) held that regulation 
in England, Wales and Northern Ireland for the retention of the fingerprints, cellular 
samples and DNA profiles of particular persons breach the European Convention on 
Human Rights (ECHR). The exact wording of the court was:  
“The Court notes at the outset that all three categories of the personal information retained 
by the authorities in the present case, namely fingerprints, DNA profiles and cellular 
samples, constitute personal data within the meaning of the Data Protection Convention as 
they relate to identified or identifiable individuals.” 80 
 
The Marper case ruling could be used to argue that personal data should encompass 
biological material. The UK Information Commissioner's Office (ICO) in addition with a 
consultation paper builds on the Marper case to argue that 'the processing of personal data 
in the form of DNA samples and profiles and fingerprints clearly engages' central 
provisions laid out in the UK Data Protection Act. 81 The court’s decision regarding 
personal data can be seen as a stretch because there is no express definition of biological 
matter being ‘personal data’ in the Data Protection Convention. There is article 2(a) that 
speaks of ‘any information relating to an identified or identifiable individual’ but the 
explicit terms of data and information are otherwise unspoken for. 82 
 
On the one hand, the Marper case brought to light the issues of human rights and data 
protection, but on the other, there seem to be some pieces missing to make this always a 
binding precedent. This case is a good start to recognizing that human rights and data 
protection should be considered together in data protection cases. This case also pushes the 
Data Protection Convention to be more directly applicable to biobanking. While it is 
 
79 Lee A. Bygrave, Data Protection Pursuant to the Right to Privacy in Human Rights 
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 39 
important to note that the Marper case provides good precedent for removal of innocent 
DNA from police records nothing extreme has changed only 377 people were removed 
from the database in 2009. 83 
4.2.3 The Nordic Countries  
Finland is interesting to examine in their view to biobanking as the Nordic countries have 
been using biobanks to collect data for years. In Finland, policy innovation has become the 
main way to deal with the governance and development of biobanking. 84  
 
In 2006, Finland started drafting a new law with regards to biobanking aiming to infuse it 
in existing laws on the matter. The main issues the new laws want to tackle is the right of 
the sample donors, respect for the existing international agreements and supporting medical 
research in Finland. 85 Finland has also adjusted their legislation to cover research on 
archived biological material that is stored.  
 
Finland has enacted a Biobank Act (Act 688/2012) that is in force since September 1, 2013. 
The Biobank Act was created to solve problems due to the overly strict informed consent 
doctrine and enable secondary uses of old samples and data.  
 
Under the Biobank Act an individual should be informed about the owner of the biobank 
and about the biobank storing the samples and data. The registered field of activities of the 
biobank serves as a limitation for the use of its samples and data. In addition, the subject 
must be informed of the general nature of biobanking and its risks, the purposes of 
collection and storage, that this is a voluntary procedure, the right to cancel or limit the 
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consent at any time. The subject also has the right to give consent to their personal data 
being disclosed or linked to register data.86 
 
A proposed idea by Finland, which was a step closer to dynamic consent, was creating a 
National Archive of Health Information (KanTa), which is currently being developed to 
serve health care, pharmacies and citizens. The services, once fully operational, would 
include electronic prescription, a Pharmaceutical Database, a My Health Information, and a 
Patient Records Archive. With this database, a person could manage and access all his or 
her health data through KanTa, including biobank consent.  
 
The Swedish Biobanks Act (2002:297), in effect as of January 1, 2003, clearly indicates 
that informed consent should be obtained for each new research project. Alongside this, the 
Swedish Ethical Review Act (2003:460), in effect as of  January 1, 2004, states that the 
research ethics committees (RECs) should strike a balance between the value of research 
and the risks of violation of privacy of the donor.87  The RECs are then responsible to 
choose the consent procedures in accordance with legislation. When participating in a study 
in Sweden participants felt no need to be asked for informed consent in relation to new 
studies on their previously collected samples, provided that the studies were approved by 
the REC. 88 
 
Additionally, in the study it became clear that in Sweden tissue donors most prefer a 
general informed consent procedure where consent is asked in the beginning of the study 
only. The participants want the REC to use their power and decide on how to use the 
previously collected samples and allow storing the material as long as it is useful for further 
research. It is still important to note that in this study the preferences for information and 
consent always depended on the context, particularly the risks of the donor and the purpose 
of the research.  
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The Swedish national biobanking program has established regional biobank registries that 
act as contact points for withdrawal of consent for all biobanks established within defined 
geographical regions.  
 
In Norway, the research use of both personal health data and samples is regulated by the 
same legislative instrument: The Health Research Act, Helseforskningsloven, hereafter the 
HRA. 89 This legislation covers specific provisions human biological material and requires 
the storage and processing of material in research biobanks to be carried out in accordance 
with the donor’s requests.  Patients should be informed that their biological material is 
being used for research and they are provided a right to withdraw this right. Additionally, 
there is an electronic register in place with patients who have stated that they do not want 
their biological material used for research purposes as seen in § 28 of the HRA. Under §12 
of the act unless specific legal authority or another valid legal basis exists, the collection, 
storage, and processing of human biological material and data for research purposes require 
consent by the donor, which should be (1) voluntary, (2) express, and (3) informed. 
Additional consent must be obtained if the biological data will be used for wider scope or 
different novel use then originally specified.  
 
It is important to note that explicit consent is not necessary needed to be received for 
research purposes if the specific conditions laid out in the HRA are met as stated in §35.90 
The REC may decide that such data can be handed over by health personnel for use in 
research if, and only if, the research in question is of significant interest to society and the 
data subject’s welfare and integrity are ensured. Importantly, when it is impossible or 
difficult to gain new consent the REC can grant an exemption from the requirement 
according to §15 of the HRA. It is crucial that the REC still specify he new or changed use 
of the research material. In addition to this, §20 stresses that anonymized material does not 
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require consent. With regard to withdraw of consent §11-13 state it is possible to withdraw 
consent at any time. The person can request any health and personal data to be erased, 
destroyed or returned unless the material was anonymized or is actively being used for 
scientific work. 
 
As we can see there are different sources of law used in each jurisdiction. This remains so 
because there is no single European legislative instrument that regulates human tissues in 
research or biomedical research as a whole. This means that each MS has a wide range of 
national laws that apply to human tissue research. Some countries have a united front for 
instance inland and Norway have implemented law that merges consent requirements for 
data and samples.91  
4.3 Self Determination and Biobanking For Research Purposes 
4.3.1 OECD Guidelines on Human Biobanking and Genetic Research Databases 
The OECD Guidelines on Human Biobanks and Genetic Research Databases (HBGRD) 
provides guidance for the establishment, governance, management, operation, access, use, 
and discontinuation of human biobanks and genetic research databases, which are 
structured resources that can be used for the purpose of genetic research on human 
biological material.  
 
The HBGRD aims to foster research and should be governed in accordance with legal 
frameworks. They should make data and materials readily available to researchers to 
advance studies and understanding. The organization is responsible to ensure development 
and maintenance of clearly documented operating procedures and policies for the 
procurement, collection, labelling, registration, processing, storage, tracking, retrieval, 
transfer, use and destruction of human biological materials, data and/ or information.  
  
The HBGRD is of high importance in biobanking not just for its storage but also for the 
consent procedures. They are responsible for the review process in accordance with 
applicable law, this includes research ethics committees and oversight mechanism with 
regard to biological materials within the consent process.  They are responsible to review 
 
91 Ibid  
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the following when biological materials are not used in a way that was originally specified 
in the original consent agreement:  
. for previously collected human biological materials or data where the use might 
deviate from the original consent;  
. for cases where informed consent may not have been obtained at the time of 
collection;  
. for determining when to seek re-consent; 
. for use of human biological materials or data where consent was obtained using a 
broader or layered format for uses unspecified at the time of collection, especially in 
the case of large-scale genetic epidemiology studies. 92 
 
The HBGRD stays neutral in the process of evaluation and works transparently. They help 
in consent procedure evaluations by ensuring that participants of studies have access to 
updates regarding the type of research they are participating in and what data is stored in 
their database. They individuals involved in the oversight process usually have a diverse 
area of expertise in regard to the materials being observed. Prior consent must always be 
obtained from each participant. “The HBGRD may provide for obtaining 
consent/authorization from an appropriate substitute decision-maker, or for obtaining 
waiver of consent from a research ethics committee or an appropriate authority, in 
accordance with applicable law and ethical principles pertaining to the protection of human 
subjects.” 93 
 
Additionally, the HBGRD is responsible on the protection of human biological materials 
and data. Before collecting of the human biological material, the operators of the database 
should make sure to provide information on how the materials and data will be protected to 
all participants. The collection of such data should also be conducted in a way that protects 
patients’ privacy and confidentiality of the sample material and the data.  According to the 
HBGRD principles human biological materials should not be transferred to other parties to 
safeguard privacy and confidentiality of participants. In addition to this, researchers should 
 
92 OECD Guidelines on Human Biobanks and Genetic Research Databases, European 
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only gain access to the human biological material in a coded and anonymized fashion so 
that the participant cannot be identified.  
 
With regard to withdrawing material from the HBGRD it is possible to do so. The HBGRD 
is responsible to dispose or transfer the biological material to the necessary entity with high 
regard to privacy and confidentiality.  
 
The HBGRD, if implemented properly, is a good way to maintain the privacy and 
confidentiality of biological materials of participants and at the same time foster research. 
The HBGRD provides safe consent mechanisms as well as opting out process for 
participants. If laid out clearly to the donors of the material this has a lot of potential to 
prevent abuse of privacy, as well as cluing in the participant into their rights. This 
demonstrates a huge step in involving the donors in the process. I believe the HBGRD has a 
good set of mechanisms in place in terms of data protection and governance on how to treat 
human biological material properly. The HBGRD can provide quality assistance to 
biobanks that need to do extra research on biological materials in a safe and reliable 
manner. The organization also fosters research and opens the door for researchers to help in 
studying certain issues in the medical world and can in the long run help biobanks yield 
high results in their research.  
 
4.3.2 Academic freedom in biobank research 
 
Angry public reaction to scandals involving human tissue and organs without consent, 
concerns with biobanks and other tissue-related controversies, is often used to justify the 
claim that the public doesn’t trust biobanking researchers.94 On the other hand, people 
generally have high levels of trust in health professionals and medical research bodies that 
their interests will be protected. 95 Empirical studies of biobanking have shown high levels 
of public trust with risks seeming to be well managed through existing regulatory systems. 
 
94 Hansson M, “Building on Relationships of Trust in Biobank Research” (2005) 31 J Med 
Ethics 415  
95 Levitt M and Weldon S, “A Well Placed Trust? Public Perceptions of the Governance of 
DNA Databases” (2005) 15 Crit Publ Health 311  
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96 With trust being on the rise toward biobanks it is essential to examine what level of 
academic freedom there is in clinical research as a whole. What are university biobanks 
rights to research and how much academic freedom do they have.  
 
University biobank projects usually began just as any other research project with an idea 
created by a researcher to pursue their interest. Other biobanks have some extra skin in the 
game with scientific value that goes beyond the project initially planned only for collecting 
and sampling data. Some examples of such projects may include how unique samples are, 
finding the samples linked in disease registries, or even that a sample could be used to 
explore a cure for a rare disease. Universities participating in such studies are valuable and 
should be adopting policies to deal with the research being done in the biobanks. The 
policies should cater to ensure freedom in individual freedoms of researchers and still 
protect the privacy and basic values of a biobank. This can be hard to balance but will be 
analyzed and discussed, nonetheless. 
 
Universities perform a lot of research on a daily basis and thus become a site where data is 
stored and collected overtime. Now universities even store resources in biobanks. Biobanks 
are important in biomedical research and often contain many samples of human biological 
materials such as tissues. University staff usually runs biobanks at the university and there 
is a lot of discrepancies sometimes on how to manage the stored data and materials. There 
are also challenges that arise when sharing data in international research collaboration as 
legal procedures vary from country to country on protecting donor rights. 97 It is interesting 
to note that although there has been a lot of biobank at universities, the institutions are not 
showing a high level of interest in developing national or international standards to sustain 
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The universities do not fall outside the scope of any other biobank standards they must 
respect the rights and privacy of donors, which comes with a significant amount of legal 
obligations. The important step to take is to make sure that informed consent was received 
from the donor. The institution that receives the sample should have a place for storage of 
the materials or data and the recipient or any information leading to their identity must not 
be named in any publications. 99  Compliance is essential now with the GDPR in place.  
 
The GDPR has mandated that personal data should be processed transparently, fairly, and 
lawfully. This new EU legislation deems consent not only a requirement but forces data to 
be processed according to the standards lied on in the regulation for it to be a lawful 
activity. According to the GDPR researchers that handle human data are bound to remove 
personal data collected by them if the data subject requests their personal data be removed. 
The only exception to this case is if the information gathered is processed for public 
interest.  
 
The GDPR also stipulates the right to erasure. The right to erasure basically states that 
when personal data can be erased upon request. According to Article 17 of the regulation 
this may apply in cases when materials are no longer necessary for the purpose of research, 
were not processed lawfully or the subject of the study withdraws their consent for further 
use of their biological materials. However, if the data being processed or archived it for 
public interest research then the right of erasure cannot be applied if it is “likely to impair 
the achievement of the objectives’ of that processing.”100 University biobanks should 
carefully study the new requirements set forth in the GDPR and have proper guidelines in 
place because ramifications can be quite strict and can impact further research within the 
biobanks.  
 
University biobanks are not just limited to the GDPR they are often also getting some sort 
of economic assets from running of the biobank. This means that they can make a profit 
from their research by protecting research results through patents, trade secrets, and protect 
their databases. Universities using biobanks for such purposes must follow the principles 
laid out in EU Recommendation CM/Rec (2016) 6, which enshrines the principles of 
 
99 Ibidem 
100 GDPR Art. 89 
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governance when obtaining, storing, or using biological materials along with 
interoperability of data for research purposes. If the university-based biobank follows this 
structure they must clarify the share of ownership of intellectual property bred within the 
framework of the biobank-based projects. In this work model there could also be the 
serious issues that need to be addressed with regard to cross- border exchange of samples 
and data transfers, which is an increasing problem within the EU harmonization of current 
biobank processes. 101 
 
Universities are required, to take measures to implement the principles set out under the 
Code of Practice annexed to Commission Recommendation C (2008) 1329 on the 
management of intellectual property in knowledge transfer activities. 102 The Code 
recognizes institutional ownership over ownership rights previously held by academic 
employees, commonly known as ‘professor’s privilege’, as the default legal regime. 103 
This means that university-run biobanks should clarify the distribution of ownership of the 
focal point intellectual property discovered in the biobank-based project. According to 
Article 3 of EC Directive 98/44/EC (Biotech Directive), inventions satisfying the basic 
patentability criteria–that is novelty, inventive step, and industrial applicability–are 
considered patentable even if they involve a product consisting of, or containing, biological 
material. Additionally, Article 5 solidifies that this principle extends to human biological 
material if it has been isolated from the human body or otherwise produced through 
technical means that has been unveiled in a patent application.  
 
Besides patent law, database rights may be applicable in university run biobanks. The 
GDPR includes specific rules on protection of databases, providing exclusivity for 
databases encompassing genomic information. This type of ownership of data/information 
will cause tension between stakeholders by having multiple groups of researchers that have 
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ownership rights. Put simply, database rights may point toward the university, the funder, 
or the researcher, as the beneficial owner. If the university follows such a model, then there 
must be proper management of intellectual property in place between all the collaborators 
involved. However, it is much more beneficial for university researchers and biobanks to 
collaborate generate and analyze data collectively, rather than protect their own high-
quality data separately. If proper management of IP is set in place and clearly arranged 
collaboration will be successful. 
 
With regard to freedom for research the GDPR ensures sufficient flexibility and reconciles 
data protection principles and research, which has wiggle room for the MS to maneuver 
domestic legislation.  Article 89(1) and 89(2) of the regulation allows for the processing of 
data for research purposes with appropriate safeguards, particularly MS should lay down 
specific safeguards for personal data that has been stored for longer periods of time than 
anticipated originally when used for scientific research. 104 This discretion allows each MS 
to find a perfect balance between protecting the individuals and safeguarding scientific 
research in obtaining their public health goals.  
 
One last factor to consider is the financial burden. When a university is trying to run a 
biobank, they could come upon financial challenges in long-term sustainability of such 
projects. Biobanks often need an extensive business plan and investment strategy. 105 
Usually network grants and research grants will not cut the cake to fully sustain a university 
biobank. The suggested solution to such a problem is that biobanks should be embedded 
with healthcare structures so that they can be used not only for research but also clinical 
purposes. 106 
 
With all this in mind, universities have to decide for themselves the extent to which they 
want to become commercialized and will have to monitor the effect the commercialization 
 
104 Article 89(1) GDPR 
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population biobanks: a new model for translation, Human Genetics (2011) Vol. 130 
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has on their research, public confidence in research, and academic freedom.107 Universities 
should re-examine every aspect of their contracts with industry, how to prevent dangerous 
relationships between faculty members and industry, and how to evolve standards for 
research practice to ensure protection of their scientific researchers if difficulties come 
about. Universities should have a clear understanding with the research facilities, biobanks 
and hospitals the partner with on the standing of laboratory specialists.   
 
4.3.3 Ethical research and analysis in biobanking 
 
Informed consent is codified in international settings in the Helsinki Declaration and 
Nuremberg Code. Respecting the autonomy of research subjects and their right to refuse to 
participate in research does stretch out through long spans of history in the research field. 
108 The concept of donors as independent agents is a key concept in research nowadays, 
thus identifying what information and freedom is necessary before a person can make an 
autonomous decision is inherent to all forms of biobanking and genomic research linked 
with human or biological specimen.  
 
Different consent methods have been discussed, but in practice biobank forms would need 
to obtain broad, specific or presumed. With the changing methods and updates necessary in 
biobanking, the suggested method seems to be dynamic, as it compromises between the 
specific and broad terms of consent. Large biobanks that are in action deem that broad 
consent is the most favorable despite the fact that there is still a debate among ethicists 
whether protects the autonomy and free will of the donors. 109 With consent models it 
seems that there will be no one method that is the ideal and in consensus with reciprocity, 
anonymity and the right to know. Thus, it is important that researchers should plan and 
conduct their research according to what the donors would expect when consenting to 
donating their samples. 
 
 
107 Somerville MA. A postmodern moral tale: the ethics of research relationships. Nat Rev 
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109 Petrini C. ‘Broad’ consent, exceptions to consent and the question of using biological 
samples for research purposes different from the initial collection purpose. Soc Sci Med  
2010;70:217–20 
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While data protection is important for protecting individual rights, it is not always the same 
as participant protection in the research field. This fact is exactly why research ethics 
committees are often involved in decision making and need to carefully weigh each 
individual research project using biobanks. In some cases, this could mean that the 
autonomy of researchers may outweigh the free will of the participants as the research may 
be necessary to promote health or prevent potential harm to the greater society. With data 
protection being a crucial issue with regard to biospecimen it is important that biobank 
projects carefully explain their reasoning for resorting to certain levels of anonymity and to 
always ensure proper consent is gained. Ethics committee members should take an active 
role in understanding data protection laws with regard to samples and data, they should 
have active trainings on how to properly evaluate risk factors on privacy of donors in each 
specific biobank project.  
 
“In Finland, biobank-related research is subject to specific legislation according to which 
primary collection of biobank materials and secondary use of data derived from those 
materials are subject to medical research law and ethical review or equivalent evaluation 
provided in that law. Data protection law is applied in a supplementary way to the 
processing of personal data relating to the materials in the biobank. In addition, the relevant 
provisions of the Finnish FoIA with regard to secrecy of personal health and social security 
information are applied to accessing data from biobanks.”110  
 
4.3.4 Genetic databases and biobanking: access to genetic privacy rights 
Biobanks create a challenge revolving around the autonomy of an individual. Storing tissue 
and DNA samples for long periods of time coupled with the possibility to create endless 
DNA copies from a single sample, cause concern that these samples could be used for 
purposes other than those for which they were originally intended.111 If unauthorized by the 
individual such as use of the sample will require additional consent from the subject.  
 
The European society of Human Genetics suggests that anonymous samples can be used for 
purposes other than originally specified, so long as the samples are irretrievable and the 
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name of the donor is not released.112 In addition to this, the UK Human Genetics 
Commission condones conducting research on old samples obtained without informed 
consent if the samples were anonymized. 113 An alternative to this that biobanks are using is 
asking open-ended permission to use their genetic information in future studies. 114  This is 
a weak form of consent because the research subject in this case will not be updated on 
where their materials are tested and for what purpose. This is a big privacy concern as then 
the subject loses rights and control over their biological material.  
 
With the rise of technology there has been increased privacy concerns as mega databases 
can hold immense amounts of information nowadays, and these databases can contain 
biological information that is not new. On the flipside with finding ways to protect genetic, 
biological and medical information has been on the rise. The creation of biobanks has 
facilitated scientific progress, for instance being useful when it comes to tissues collected 
being stored in databases adding value to healthcare systems and pharmaceuticals, 115but 
they also added new privacy concerns in the mix.  
 
These new technological developments have led the private sector to become increasingly 
involved in collecting, assembling, and linking genetic information, through partnerships 
with government or research institutions that willingly transfer individuals' genetic material 
and/or information to the hands of the private sector. 116 This can be a problem since the 
private sector is only interested in making money, they have no interest in protecting the 
public interest. Therefore, there is a danger of these parties to not provide adequate enough 
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safeguards to ensure the subjects privacy. The private sector can misuse the sensitive 
information simply to make some extra money.  
 
There is an important need to focus on the fact that there is a lack of restrictions and 
guidelines on private companies on storage of genetic information. Private companies are 
free to choose how much security and what due care steps they take to ensure that the 
sensitive data does not get out, and how they store and collect the information. With this 
there is a clear discrepancy in how sensitive information is stored and handled, which 
breaches privacy interests of the data subjects and creates confusion in conducting proper 
genetic research. 117  
 
The European Union allows personal information to be transferred only to nations that 
grant sufficient privacy protection measures. Limitations on transfers of genetic 
information include restrictions on the information's location, the receiving entity and 
future usages are required. 118 There is a definite need for extra scrutiny when it comes to 
sharing sensitive data with the private sector. Strict supervision must be implemented when 
partnering with for profit companies or third parties on research projects, particularly being 
careful when a partnership between private and public sectors is initiated.  
 
The best suggestion in solving this problem is harmonization of the rights on storing and 
handling sensitive data. There should be a uniform rule on how private companies shall 
behave with such data. Adequate consent rights should be implemented with sensitive data. 
Lastly, there should be limitations or restrictions on compiling and using sensitive 
biological data.  
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5.1 Findings  
Data portability increases informational self determination of the data subject. Data 
portability should provide the data subject with the control over the personal data.  
It is no question that informational self determination is directly linked with information 
privacy. The data subject may determine to whom they disclose their personal data if at all. 
Their decision on this matter should be made freely without any undue influence from a 
third party for informational self determination is preserved. Nonetheless, the right to data 
portability, provides a means for providers to attract users with even more personalized 
services. These developments can result in lax rules on privacy protection of informational 
privacy of the data subjects for various reasons, whether to make profit or to promote 
research.  
 
For our purposes it is important to note that the right to data portability only applied to 
personal data. Therefore, this leads to the idea that data portability does not apply to 
anonymous data.119 Yet, pseudonymous data that can clearly be linked to a specific 
individual is still within the scope of this right. Notably, the GDPR does not specify how 
individuals should make data portability requests. Therefore, requests could be made 
verbally or in writing. A request does not need to include the phrase ‘request for data 
portability’ nor does it need any reference to Article 20 of the GDPR.  
 
While the GDPR provides the option of data portability there are exemptions for biobanks 
from a number of GDPR principles and data subject rights if and when the personal data is 
being processed for scientific research. 
 
Informational self determination can be viewed as a proprietary right to personal data. Data 
portability is the transfer of an object, taken from one place to another and handed over, in 
our case the data transfer is the data subjects personal data. Data portability as proposed in 
the General Data Protection Regulation as two relatively separate rights, the right to obtain 
 




a copy from the controller and the right to data transfer.120 Even though, these rights 
enhance informational self determination, they do not guarantee full control over personal 
data, as there is even differentiation on when the data portability can be extended based on 
the necessity of the material gathered from the data subject.   
 
Consent for our purposes is an essential addition to the GDPR, particularly informed 
consent, which allows the individual to agree to data processing options and who gets 
access to their data. Privacy self-management allows people the right to take notice of how 
their personal data is being collected and used and need to decide whether or not they 
consent to such use of their data. 
 
The right to withdraw consent was founded in The Declaration of Helsinki, The Nuremberg 
Code, CIOMS, as well as the Convention of human rights. It is also recently covered in the 
GDPR. The Declaration of Helsinki 1964 the demand for unrestricted individual rights to 
withdraw consent to participate in research is on the rise.  
 
The Nuremberg Code saw research as a common good and idealized experimental subject 
as a greater good for humanitarian projects leading to different view on withdrawal 
rights121, whereas the Helsinki Declaration provided the individual the right to withdraw 
regardless of the reasoning allowing for more freedom. The right to withdraw consent does 
not imply a right to withdraw results that have already accumulated, rather it implies that 
new data cannot be obtained, and that existing data must be maintained in an 
impersonalized form. 
 
Although there was already the concept of individual rights in to stop participation in 
studies before in the Nuremberg Code of 1947, the Helsinki Declaration provided a clearer, 
easier way on how to do this.  
 
The GDPR does not say that giving and withdrawing consent must always be done through 
the same action. The requirement of an easy withdrawal is described as a necessary aspect 
 
120 Eva Fialova, Data Portability and informational self-determinaton, Masaryk University 
Journal of Law and Technology, Vol. 8:1, 2014 
121 See further: The Nuremberg Code, 1947, BMJ 1996 
 55 
of valid consent in the GDPR. If the withdrawal right does not meet the GDPR 
requirements, then the consent mechanism of the controller does not comply with the 
GDPR. 
 
The GDPR has mandated that personal data should be processed transparently, fairly, and 
lawfully. This new EU legislation deems consent not only a requirement but forces data to 
be processed according to the standards lied on in the regulation for it to be a lawful 
activity. According to the GDPR researchers that handle human data are bound to remove 
personal data collected by them if the data subject requests their personal data be removed. 
The only exception to this case is if the information gathered is processed for public 
interest.  
 
According to many regulations and guidelines, there is no need to destroy a sample when a 
participant withdraws from a study, since anonymization can solve the problem. Data 
protection in health research led to debates during the legislative process, in particular 
regarding whether there should be exemptions from the obligation to always seek consent 
before using patients’ data for research in cases where asking for consent or re-consent is 
impossible (Article 89). 
 
The argument for anonymization is linked to the fact that information derived from a 
participant’s tissue cannot be used at their disadvantage if no one can find out their identity. 
The data subject does have the right to end participation in a study, but since it can be of 
importance to keep the sample for research, de-identification is the more preferred solution. 
Anonymization means that the participant is no longer participating; only the anonymous 
tissues are being observed, with no researchers gaining access to the identity of the donor. 
However, at the end of the day, ties from the donor still cannot be cut.  
 
The HBGRD is of high importance in biobanking not just for its storage but also for the 
consent procedures. They are responsible for the review process in accordance with 
applicable law, this includes research ethics committees and oversight mechanism with 
regard to biological materials within the consent process.   
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The HBGRD is responsible on the protection of human biological materials and data. 
Before collecting of the human biological material, the operators of the database should 
make sure to provide information on how the materials and data will be protected to all 
participants. The collection of such data should also be conducted in a way that protects 
patients’ privacy and confidentiality of the sample material and the data.  According to the 
HBGRD principles human biological materials should not be transferred to other parties to 
safeguard privacy and confidentiality of participants. In addition to this researchers should 
only gain access to the human biological material in a coded and anonymized fashion so 
that the participant cannot be identified.  
 
5.2 Recommendations/Commentary 
With regards to consent models I think that the most appropriate form of consent in 
biobanking is dynamic consent. Dynamic consent allows for constant communication with 
the tissue donors and for them to change their preferences allowing them to be in control of 
where their materials go and to what study. The fact that the dynamic consent model 
informs research participants about the research they are involved in is essential in all types 
of research consent processes.  This method better distributes detailed information 
compared with broad consent. Additionally, dynamic consent increases trust and 
willingness to participate in research. The aim of dynamic consent is to be more inclusive 
compared with regimens utilizing broad consent.  
 
This method of consent is also more applicable with the GDPR as it provides a specific and 
informed explanation of where the sample will be used and for what purposes. On the other 
hand, dynamic consent seems to go against Article 9(2) with regards to sensitive data, but I 
think that this is a good thing as it is an infringement of fundamental rights.  
 
From my research I am of the opinion that privacy law often relies too much on privacy 
self-management. Privacy self-management cannot achieve privacy alone. Many privacy 
issues are inherently linked with the consent dilemma. A coherent approach to consent must 
be developed in legal framework, taking into account how individuals actually make 
decisions about their personal data. It is also important to develop more substantial privacy 
rules and timing necessary for consent. While, an individual can take part in privacy self-
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management it is important to remember that individuals can often only participate in this 
selectively and if they fully understand what they are consenting to.  
 
One of the biggest dilemmas in data protection of personal data has been finding a balance 
between informational self-determination and an individual’s control over their data with 
the competing interest of the one’s collecting, using and processing their data. Yet, in my 
research I determined that the right of informational self-determination prevents enterprises 
or government agencies from doing whatever they want with the data of private citizens. 
This legislation guarantees the fundamental right of individuals to determine whether and 
how their data should be used or released. 
 
As biobanks process ‘personal data’, European data protection law applies in their day-to-
day operations. Despite the clear evidence that data protection law applies, there remains 
uncertainty about the exact application of the General Data Protection Regulation. There 
are questions if open consent is legitimate is one such uncertainty. On top of this there is a 
wide range of opinions on what types of consent is applicable in the use of sensitive data. In 
addition to this, the GDPR requires that any consent be ‘specific’ and ‘informed’. This 
could pose a problem for biobanks operating with open consent as they cannot meet these 
requirements.  
 
According to extensive research most ethical guidelines are for the protection of withdrawal 
of consent in biobank research. However, there are no explicit explanations as to why this 
should be an available remedy within these documents. Invoking the right to withdraw 
consent is important for the public to have trust in researchers and will promote more 
participants if they know they have an option to opt-out or remain in the biobank research 
process.  
 
Anonymization is often the go-to solution for protecting privacy in biobanking but it should 
not be the default setting of from researchers and biobank holders when requests of 
withdrawal occur. On the other hand, a request for withdrawal should not stop research on 
identifiable samples. Instead of the present emphasis on individuals’ right to withdraw 
consent to research on their biological samples for any reason, the clause on withdrawal in 
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the Nuremberg Code be included in guidelines on biobank research.122 This would allow 
anonymization as a solution to the withdrawal of samples and promote further research on 
the tissue in question. Although there would also have to be reforms on researchers requests 
of the samples and a way to ensure that the information of the donor doesn’t get released 
through medical journals.  
 
The HBGRD if implemented properly is a good way to maintain the privacy and 
confidentiality of biological materials of participants and at the same time foster research. 
The HBGRD provides safe consent mechanisms as well as opting out process for 
participants. If laid out clearly to the donors of the material this has a lot of potential to 
prevent abuse of privacy, as well as cluing in the participant into their rights. This 
demonstrates a huge step in involving the donors in the process. I believe the HBGRD has a 
good set of mechanisms in place in terms of data protection and governance on how to treat 
human biological material properly. The HBGRD can provide quality assistance to 
biobanks that need to do extra research on biological materials in a safe and reliable 
manner. The organization also fosters research and opens the door for researchers to help in 
studying certain issues in the medical world and can in the long run help biobanks yield 
high results in their research. 
 
Universities have to decide for themselves the extent to which they want to become 
commercialized and will have to monitor the effect the commercialization has on their 
research, public confidence in research, and academic freedom.123 Universities should re-
examine every aspect of their contracts with industry, how to prevent dangerous 
relationships between faculty members and industry, and how to evolve standards for 
research practice to ensure protection of their scientific researchers if difficulties come 
about. Universities should have a clear understanding with the research facilities, biobanks 
and hospitals the partner with on the standing of laboratory specialists.   
 
Open-ended permission to use their genetic information in future studies is a weak form of 
consent because the research subject in this case will not be updated on where their 
 
122 Ibid 
123 Somerville MA. A postmodern moral tale: the ethics of research relationships. Nat Rev 
Drug Discov (2002) 1:316-20.  
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materials are tested and for what purpose. This is a big privacy concern as then the subject 
loses rights and control over their biological material.  
 
The European Union allows personal information to be transferred only to nations that 
grant sufficient privacy protection measures. Limitations on transfers of genetic 
information include restrictions on the information's location, the receiving entity and 
future usages are required. 124 There is a definite need for extra scrutiny when it comes to 
sharing sensitive data with the private sector. Strict supervision must be implemented when 
partnering with for profit companies or third parties on research projects, particularly being 
careful when a partnership between private and public sectors is initiated.  
 
The best suggestion in solving this problem is harmonization of the rights on storing and 
handling sensitive data. There should be a uniform rule on how private companies shall 
behave with such data. Adequate consent rights should be implemented with sensitive data. 
Lastly, there should be limitations or restrictions on compiling and using sensitive 
biological data.  
 
 
124 See further:  France Fukuama, The Political Control of Biotechnology, in Our 
Posthuman Future: Consequences of the Biotechnology Revolution 181, 181-94 (2002)  
 
